Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genentech gets Inotek rights
July 31, 2006
| A version of this story appeared in
Volume 84, Issue 31
Genentech and Inotek Pharmaceuticals will jointly develop and commercialize inhibitors of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme involved in the repair of damaged DNA, for the treatment of cancer. Inotek will receive a $20 million up-front payment and could reap an additional $405 million in milestone payments. Genentech will pay Inotek royalties on its lead PARP inhibitor, INO-1001, currently in Phase Ib testing for skin cancer. As part of the deal, Genentech also has the option to develop Inotek's PARP inhibitors for cardiovascular indications. If exercised, the option could be worth another $200 million to Inotek.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter